Coherus Oncology, Inc.
- CHRS · Nasdaq
- Biological Products, (No Diagnostic Substances)
- Redwood City, CA
- 147 employees
- CIK 0001512762
Updated from SEC filings through
Top things to know
Executives
-
Dennis M. Lanfear President & CEO 4, 2026-06-02 -
Bryan J. McMichael Chief Financial Officer 4, 2026-06-02 - Bryan McMichael Chief Financial Officer 10-K, 2026-03-09
What leadership is saying
“The strategic prioritization of esophageal cancer as our best-in-disease focus for tagmokitug, together with the Transition Services Agreement wind-down and the toripalimab process transfer completion, provides an ideal opportunity to right-size the organization and deliver financial benefits that flow directly from this prioritization”
Earnings press release (8-K Ex. 99.1), filed November 9, 2026
Coherus Oncology, Inc. is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in Redwood City, CA. It trades as CHRS on Nasdaq. Revenue was $42.2M in the fiscal year ending December 31, 2025, +59.8% from the year before. It reported about 147 employees. Dennis M. Lanfear is President & CEO.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $42.2M 10-K, 2026-03-09 | $26.4M 10-K, 2026-03-09 | $1.2M 8-K, 2025-11-13 | $211M 10-K, 2025-03-17 | $327M 10-K, 2024-03-15 |
| Operating income | -$181M 10-K, 2026-03-09 | -$200M 10-K, 2026-03-09 | -$216M 8-K, 2025-11-13 | -$257M 10-K, 2025-03-17 | -$264M 10-K, 2024-03-15 |
| SG&A | $101M 10-K, 2026-03-09 | $125M 10-K, 2026-03-09 | $120M 8-K, 2025-11-13 | $198M 10-K, 2025-03-17 | $170M 10-K, 2024-03-15 |
| Net income | $168M 10-K, 2026-03-09 | $28.5M 10-K, 2026-03-09 | -$238M 8-K, 2025-11-13 | -$292M 10-K, 2025-03-17 | -$287M 10-K, 2024-03-15 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Dennis M. Lanfear | President & CEO | 4, 2026-06-02 |
| Bryan J. McMichael | Chief Financial Officer | 4, 2026-06-02 |
| Bryan McMichael | Chief Financial Officer | 10-K, 2026-03-09 |
| Mats L. Wahlström | Board member (per proxy) bio: director | DEF 14A, 2026-04-20 |
| Rita A. Karachun | Board member (per proxy) bio: director | DEF 14A, 2026-04-20 |
| Ali J. Satvat | Director | 10-K, 2026-03-09 |
| Charles W. Newton | Director | 10-K, 2026-03-09 |
| Georgia Erbez | Director | 10-K, 2026-03-09 |
| Jill O’Donnell-Tormey | Director | 10-K, 2026-03-09 |
| Lee N. Newcomer | Director | 10-K, 2026-03-09 |
| Mats Wahlström | Director | 10-K, 2026-03-09 |
| Michael Ryan | Director | 10-K, 2026-03-09 |
| Rita Karachun | Director | 10-K, 2026-03-09 |
What Coherus Oncology, Inc. does
We are a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal and other cancers. Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma (“NPC”) and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our partners, driving sales multiples and synergies from proprietary combinations.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 154.5 million (as of October 31, 2026) | 10-Q, November 9, 2026 |
|---|---|---|
| Public float | $81.9M (as of June 30, 2025) | 10-K, March 9, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 9, 2026 |
| Latest proxy statement | Meeting May 27, 2026 (filed April 20, 2026) | DEF 14A, April 20, 2026 |
| Auditor | Ernst & Young LLP (San Francisco, California) | Latest 10-K |
Recent 8-K events
- 8-K filed 2026-10-29
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-08-28
- Item 8.01 Other events
- 8-K filed 2026-08-17
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-08-17
- Item 1.01 Entry into a material definitive agreement
- Item 1.02 Termination of a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2026-08-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-15
- Item 4.01 Changes in registrant's certifying accountant
- 8-K filed 2026-06-01
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-11
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-09
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-02-17
- Item 8.01 Other events
Frequently asked questions about Coherus Oncology, Inc.
- What does Coherus Oncology, Inc. do?
- In its own words, from Item 1 of its 10-K: "We are a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal and other cancers. Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma (“NPC”) and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our partners, driving sales multiples and synergies from proprietary combinations."
- What is Coherus Oncology, Inc.'s revenue?
- $42.2M for the fiscal year ending December 31, 2025, from its 10-K filed March 9, 2026.
- Is Coherus Oncology, Inc. profitable?
- Coherus Oncology, Inc. reported net income of $168M for the fiscal year ending December 31, 2025.
- How many employees does Coherus Oncology, Inc. have?
- About 147, as stated in its annual report.
- Who is the CEO of Coherus Oncology, Inc.?
- Dennis M. Lanfear, President & CEO, as named in a 4 filed June 2, 2026.
- Who is the CFO of Coherus Oncology, Inc.?
- Bryan J. McMichael, Chief Financial Officer, as named in a 4 filed June 2, 2026.
- Where is Coherus Oncology, Inc. headquartered?
- Redwood City, CA.
- What is Coherus Oncology, Inc.'s stock ticker?
- CHRS on Nasdaq.
- What industry is Coherus Oncology, Inc. in?
- Biological Products, (No Diagnostic Substances), SIC code 2836.
- What is Coherus Oncology, Inc.'s website?
- coherus.com.
- When does Coherus Oncology, Inc. report earnings next?
- November 9, 2026. Source: pg_earnings_events.
- Is Coherus Oncology, Inc. a public company?
- Yes. Coherus Oncology, Inc. files with the SEC under CIK 0001512762 and trades as CHRS.
- Who audits Coherus Oncology, Inc.?
- Ernst & Young LLP, San Francisco, California, as named in its latest annual report (10-K).
- How many shares of Coherus Oncology, Inc. are outstanding?
- 154.5 million shares as of October 31, 2026, from its 10-Q filed November 9, 2026.
- What is Coherus Oncology, Inc.'s public float?
- $81.9M as of June 30, 2025, as reported on the cover of its 10-K filed March 9, 2026.
- How many business segments does Coherus Oncology, Inc. report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 9, 2026.
- When is Coherus Oncology, Inc.'s annual shareholder meeting?
- May 27, 2026, per its proxy statement (DEF 14A) filed April 20, 2026.